Background/Aims: Olive leaf extract (OLE) has been used for many years to benefit human health. OLE phenolics have shown therapeutic effects on a range of ailments including; obesity (satiety), cardiovascular disease and cancer. However, the mode of action is not entirely clear. The aim of this study was to identify the genes that respond to OLE to determine underlying mechanisms that correlate to health benefits. A double blind placebo controlled trial design was performed. Secondary aims include studying inflammatory and apoptosis effects of OLE in cell models.
Methods: Gene expression profiles of peripheral blood mononuclear cells (PBMCs) from healthy male volunteers (n=29) were analysed using RNA samples for Affymetrix arrays following an 8-week intervention with a 30ml daily consumption of either OLE or placebo. Difference between groups was determined with one-way ANOVA. Gene expression is being verified by RT-PCR. Nucleotide-binding oligomerization domain-containing protein (NOD)2 and HEK-Blue™-2 and 4cells were analysed for inflammatory response to OLE. 50% survival has been determined for MCF-7 (breast) and LNCap (prostate) cancer cell lines and RT-PCR used to measure differential gene expression.
Results: An interim analysis of the human samples has indicated down-regulated genes that are important in cell proliferation, differentiation, and inflammatory pathways. OLE in cell models demonstrated a strong anti-inflammatory profile in comparison to placebo.
Conclusions: The data in this project supports a gene expression level manipulation by OLE creating health benefits to humans through effects on cell proliferation, differentiation and inflammatory pathways.
Funding Source(s): Comvita Innovation & Callaghan Institute of Innovation